ABEO

Abeona Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality0/10
  • Growth↑ 9/10
  • Value↑ 5/10
Abeona Therapeutics sales and earnings growth
ABEO Growth
Great
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 186.45%
  • FCF Y/Y↓ -44.24%
Abeona Therapeutics gross and profit margin trends
ABEO Profitability
Great
  • Gross margin ↑ 73.70%
  • EPS margin↑ 1223.10%
  • ROIC 5Y↑ -44.30%
Abeona Therapeutics net debt vs free cash flow
ABEO Risk
Great
  • Debt / Equity↓ 0.2
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 20.1

Abeona Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗